BioCryst Pharmaceuticals BCRX Change in receivables
Change in receivables at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInReceivables.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's change in receivables.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's change in receivables?
- BioCryst Pharmaceuticals (BCRX) reported change in receivables of $474K in Q1 2026.
- How has BioCryst Pharmaceuticals's change in receivables changed year-over-year?
- BioCryst Pharmaceuticals's change in receivables decreased by 96.6% year-over-year, from $13.99M to $474K.
- What is the long-term trend for BioCryst Pharmaceuticals's change in receivables?
- Over 3 years (2021 to 2025), BioCryst Pharmaceuticals's change in receivables has grown at a 18.3% compound annual growth rate (CAGR), from $22.21M to $36.81M.
- What does change in receivables mean?
- Change in total receivables including trade and non-trade receivables.